Fig. 3: Copy Number Alteration Profile in Baseline Sample. | npj Precision Oncology

Fig. 3: Copy Number Alteration Profile in Baseline Sample.

From: Immunologic correlates in a CIC::DUX4 fusion-positive sarcoma responsive to dual immune checkpoint blockade

Fig. 3

Normalized log2 coverage fold changes (log-ratios) of baseline tumor versus normal sample for all captured regions in the MSK-IMPACT assay illustrating copy number alterations (CNA. Circular binary segmentation algorithm was used to segment the data; red lines denote the resulting segmented regions. Each dot represents probe set. CIC amplification is clearly detectable (fold change (FC) ≥ 2.0), whereas other potential CNA should be interpreted with caution due to low molecular purity (0.25). Notably, MYC exhibits copy number gain (FC ≥ 1.5 but <2), but does not meet the amplification threshold.

Back to article page